Long before the advent of the biologic agents, methotrexate was the gold standard for the treatment of moderate to severe psoriasis. Although methotrexate's therapeutic efficacy in the treatment of psoriasis is well-established, the mechanism of action is still poorly understood.
Objective
This paper reviews the published research on methotrexate's mechanism of action in psoriasis.
Methods
Studies published with English abstracts between January 1970 and December 2006 identified in MEDLINE with the keywords methotrexate, psoriasis and mechanism were reviewed.
Results
Methotrexate appears to exert clinical efficacy in psoriasis by interfering with CLA+ T-cell infiltration into lesional skin via multiple mechanisms.
Conclusion
It is likely that methotrexate interferes with the inflammatory pathways critical to psoriasis pathogenesis by multiple mechanisms. Current evidence suggests that methotrexate works by decreasing the number of circulating CLA+ T cells; decreasing inflammatory infiltrate into the dermis and epidermis by downregulating adhesion molecules in endothelial cells; and downregulating the expression of adhesion molecules on T cells.
Get full access to this article
View all access options for this article.
References
1.
RoenigkH.H.Jr., AuerbachR., MaibachH., WeinsteinG., LebwohlM.Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol.1998; 38(3): 478–85.
2.
EdmundsonW.F., GuyW.B.Treatment of psoriasis with folic acid antagonists. AMA Arch Derm.1958; 78(2): 200–3.
KormeiliT., LoweN.J., YamauchiP.S.Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. Br J Dermatol.2004; 151(1): 3–15.
5.
SchwartzP.M., BarnettS.K., AtillasoyE.S., MilstoneL.M.Methotrexate induces differentiation of human keratinocytes. Proc Natl Acad Sci U S A.1992; 89(2): 594–8.
6.
JeffesEW3rd, McCulloughJ.L., PittelkowM.R.Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol.1995; 104(2): 183–8.
7.
HeenenM., LaporteM., NoelJ.C., de GraefC.Methotrexate induces apoptotic cell death in human keratinocytes. Arch Dermatol Res.1998; 290(5): 240–5.
8.
PolA., BergersM., SchalkwijkJ.Comparison of antiproliferative effects of experimental and established antipsoriatic drugs on human keratinocytes, using a simple 96-well-plate assay. In Vitro Cell Dev Biol.2003; 39(1-2): 36–42.
9.
YaziciA.C., TursenU., ApaD.D.The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment. Arch Dermatol Res.2005; 297(6): 249–55.
10.
Hannuksela-SvahnA., PaakkoP., AutioP., ReunalaT., KarvonenJ., VahakangasK.Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Derm Venereol.1999; 79(3): 195–9.
11.
MiraccoC., PellegrinoM., FloriM.L., VattiR., MaternoM., AndreassiL.Cyclin D1, B and A expression and cell turnover in psoriatic skin lesions before and after cyclosporin treatment. Br J Dermatol.2000; 143(5): 950–6.
12.
BoumaM.G., van den WildenbergF.A., BuurmanW.A.Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol.1996; 270(2 Pt 1): C522–9.
13.
SigmundsdottirH., JohnstonA., GudjonssonJ.E., BjarnasonB., ValdimarssonH.Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin. Exp Dermatol.2004; 13(7): 426–34.
14.
YamasakiE., SomaY., KawaY., MizoguchiM.Methotrexate inhibits proliferation and regulation of the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by cultured human umbilical vein endothelial cells. Br J Dermatol.2003; 149(1): 30–8.
15.
Dahlman-GhozlanK., OrtonneJ.P., HeilbornJ.D., StephanssonE.Altered tissue expression pattern of cell adhesion molecules, ICAM-1, E-selectin and VCAM-1, in bullous pemphigoid during methotrexate therapy. Exp Dermatol.2004; 13(2): 65–9.
16.
HirataS., MatsubaraT., SauraR., TateishiH., HirohataK.Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum.1989; 32(9): 1065–73.
17.
CreamerD., AllenM.H., SousaA., PostonR., BarkerJ.N.Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol.1997; 136(6): 859–65.
18.
FiehnC., WunderA., KrienkeS., MaxR., HoA.D., MoehlerT.Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate. Rheumatol Int.2005; 25(2): 108–13.
19.
MorhennV.B., OrenbergE.K., KaplanJ., PfendtE., TerrellC., EnglemanE.G.Inhibition of a Langerhans cell-mediated immune response by treatment modalities useful in psoriasis. J Invest Dermatol.1983; 81(1): 23–7.
20.
LiuH.N., WongC.K.In vitro immunosuppressive effects of methotrexate and azathioprine on Langerhans cells. Arch Dermatol Res.1997; 289(2): 94–7.
21.
JohnstonA., GudjonssonJ.E., SigmundsdottirH., LudvikssonB.R., ValdimarssonH.The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol.2005; 114(2): 154–63.
22.
PhillipsD.C., WoollardK.J., GriffithsH.R.The antiinflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol.2003; 138(3): 501–11.
23.
HermanS., ZurgilN., DeutschM.Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res.2005; 54(7): 273–80.
24.
ConstantinA., Loubet-LescoulieP., LambertN.Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum.1998; 41(1): 48–57.
25.
MagariK., MiyataS., NishigakiF., OhkuboY., MutohS., GotoT.Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol.2003; 30(10): 2193–200.
26.
NeurathM.F., HildnerK., BeckerC.Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol.1999; 115(1): 42–55.
27.
SeitzM., LoetscherP., DewaldB.Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol.1995; 34(7): 602–9.
28.
PartschG., SteinerG., LeebB.F., DunkyA., BroilH., SmolenJ.S.Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol.1997; 24(3): 518–23.
29.
PartschG., WagnerE., LeebB.F., BroilH., DunkyA., SmolenJ.S.T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis.1998; 57(11): 691–3.
30.
DolhainR.J., TakP.P., DijkmansB.A., De KuiperP., BreedveldF.C., MiltenburgA.M.Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol.1998; 37(5): 502–8.
31.
KraanM.C., ReeceR.J., BargE.C.Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum.2000; 43(8): 1820–30.
32.
GerardsA.H., de LathouderS., de GrootE.R., DijkmansB.A., AardenL.A.Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford)2003; 42(10): 1189–96.
33.
HildnerK., FinottoS., BeckerC.Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis. Clin Exp Immunol.1999; 118(1): 137–46.
34.
LangeF., BajtnerE., RintischC., NandakumarK.S., SackU., HolmdahlR.Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. Ann Rheum Dis.2005; 64(4): 599–605.
35.
WeinblattM.E., CoblynJ.S., FoxD.A.Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med.1985; 312(13): 818–22.
36.
AbramsJ.R., KelleyS.L., HayesE.Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med.2000; 192(5): 681–94.
37.
BonishB., JullienD., DutroncY.Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol.2000; 165(7): 4076–85.
38.
GottliebA.B., GrossmanR.M., KhandkeL.Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol.1992; 98(3): 302–9.
39.
HuangB.B., BonishB.K., ChaturvediV., QinJ.Z., NickoloffB.J.Keratinocyte CDw60 expression is modulated by both a Th-1 type cytokine IFN-gamma and Th-2 cytokines IL-4 and IL-13: relevance to psoriasis. J Invest Dermatol.2001; 116(2): 305–12.
40.
JohnstonC., RussellA.S., AaronS.The effect of in vivo and in vitro methotrexate on lymphocyte proliferation as measured by the uptake of tritiated thymidine and tritiated guanosine. Clin Exp Rheumatol.1988; 6(4): 391–3.
41.
BakerB.S., SwainA.F., GriffithsC.E., LeonardJ.N., FryL., ValdimarssonH.Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment. Clin Exp Immunol.1985; 61(3): 526–34.
42.
BarsigJ., YamG., LehnerM.D., BeumeR.Methotrexate treatment suppresses local cytokine and chemokine production in rat adjuvant arthritis. Drugs Exp Clin Res.2005; 31(1): 7–11.
43.
FairbanksL.D., RuckemannK., QiuY.Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?Biochem J.1999; 342(Pt 1): 143–52.
44.
MoritaY., FukazawaT., HirashimaM.The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production. Scand J Rheumatol.2006; 35(4): 268–72.
45.
BarreraP., BoerboomsA.M., DemackerP.N., van de PutteL.B., GallatiH., van der MeerJ.W.Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate. Br J Rheumatol.1994; 33(11): 1017–24.
46.
CronsteinB.N.Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum.1996; 39(12): 1951–60.
47.
CutoloM., SulliA., PizzorniC., SerioloB., StraubR.H.Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Rheum Dis.2001; 60(8): 729–35.
48.
SegalR., MozesE., YaronM., TartakovskyB.The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum.1989; 32(4): 370–7.
49.
SeitzM.Molecular and cellular effects of methotrexate. Curr Opin Rheumatol.1999; 11(3): 226–32.
50.
KawashimaK., DoiH., ItoY., ShibataM.A., YoshinakaR., OtsukiY.Evaluation of cell death and proliferation in psoriatic epidermis. J Dermatol Sci.2004; 35(3): 207–14.
51.
Wrone-SmithT., MitraR.S., ThompsonC.B., JastyR., CastleV.P., NickoloffB.J.Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol.1997; 151(5): 1321–9.
52.
EskicirakB., ZemheriE., CerkezogluA.The treatment of psoriasis vulgaris: 1% topical methotrexate gel. Int J Dermatol.2006; 45(8): 965–9.
53.
SyedT.A., HadiS.M., QureshiZ.A., NordstromC.G., AliS.M.Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: a placebo-controlled, double-blind study. J Cutan Med Surg.2001; 5(4): 299–302.
54.
SigmundsdottirH., GudjonssonJ.E., JonsdottirI., LudvikssonB.R., ValdimarssonH.The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol.2001; 126(2): 365–9.
55.
ChladekJ., GrimJ., MartinkovaJ.Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol.2002; 54(2): 147–56.
56.
ChladekJ., MartinkovaJ., SimkovaM., VaneckovaJ., KoudelkovaV., NozickovaM.Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol.1998; 53(6): 437–44.
